I literally just finished saying the exact same th
Post# of 147891
“We’re proud of how far we’ve come in such a short time. From 2013 to 2021 we’ve initiated 8 programs that have given us tremendous insight into what Leronlimab is capable of. Clearly, from what we’ve seen through these programs, Leronlimab is a platform drug. In 2022 we believe we will see the fruits of our labor as we anticipate approval of Leronlimab for HIV, and potentially for Longhaulers and Covid. Additionally, we are waiting on the FDA to respond to our request for mTNBC breakthrough designation and up to three more BTD’s we’ll be submitting in the coming months covering our cancer and NASH programs. It’s a great time to be an investor in Cytodyn. Let’s start with our NASH results…”
There. Fixed it.